Xtranet-ISA

An innovative Swedish SME will soon launch a life-saving test for one of the most lethal and hard-to-detect forms of cancer. Clinically validated in an EU-funded project, the test could revolutionise the diagnosis of pancreatic cancer, providing early detection with unprecedented accuracy, boosting patient survival rates and enabling widespread screening of high-risk groups.